MEGAN MANCINELLI: Open Payments
NPI 1912684408 · TORRINGTON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,214 in 108 payments from 10 companies in 2025. Trend: 2023 $442 · 2024 $2,525 · 2025 $2,214
Food & beverage: $2,214
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 38 | $751 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 32 | $637 |
| Teva Pharmaceuticals USA, Inc. | 15 | $272 |
| Janssen Pharmaceuticals, Inc | 7 | $148 |
| E.R. Squibb & Sons, L.L.C. | 4 | $117 |
| Vanda Pharmaceuticals Inc. | 4 | $103 |
| Alkermes, Inc. | 3 | $72 |
| Neurocrine BioSciences, Inc. | 2 | $56 |
| Lundbeck LLC | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
Products named: VRAYLAR, CAPLYTA, AUSTEDO XR, UZEDY, COBENFY, INVEGA SUSTENNA, FANAPT, INGREZZA.
Industry payments across CT — which companies pay providers there.
